{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-015338","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.174015+00:00","generated_at":"2026-05-19T04:40:13.978567+00:00","sec_items":["5.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oncocyte renames to Insight Molecular Diagnostics (iMDx), ticker changes to IMDX on June 18","bullets":["Company changed name from Oncocyte Corp to Insight Molecular Diagnostics Inc. effective June 13, 2025.","Stock ticker changes from OCX to IMDX, effective before market open on June 18, 2025.","Principal executive office relocated from Irvine, CA to Nashville, TN; CLIA lab already in Nashville.","Product rebranding: VitaGraft Kidney (LDT) → GraftAssureCore, RUO kit → GraftAssureIQ, future IVD kit → GraftAssureDx.","CEO letter reports progress toward FDA submission of transplant rejection test kit; three top-10 US transplant centers engaged."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-015338","json":"https://secwatch.observer/filing/0001641172-25-015338.json","markdown":"https://secwatch.observer/filing/0001641172-25-015338.md","text":"https://secwatch.observer/filing/0001641172-25-015338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/0001641172-25-015338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:40:13.978567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4014a773c55f849ba1d8be0b6468de3c36636415","claim":"Insight Molecular Diagnostics Inc.: Amended Article I of Articles of Incorporation to change company name from Oncocyte Corporation to Insight Molecular Diagnostics Inc (effective 2025-06-13).","evidence_excerpt":"In connection with the Name Change, the Company filed a Certificate of Ownership with the Secretary of State of the State of California on June 13, 2025, to amend Article I of the Company’s Articles of Incorporation solely to reflect the Company’s new corporate name.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/0001641172-25-015338-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-06-13"}],"fact_type":"governance_change"},{"claim_id":"fb7e746e9b46d0fc3d52b8c29f8b2ac553f12545","claim":"Insight Molecular Diagnostics Inc.: Amended and restated bylaws (Third Amended and Restated Bylaws) solely to reflect the company name change (effective 2025-06-13).","evidence_excerpt":"Also on June 13, 2025, the Company amended and restated the Company’s Second Amended and Restated Bylaws (the “Third Amended and Restated Bylaws”) solely to reflect the Name Change.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/0001641172-25-015338-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-06-13"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}